---
title: "Glaucoma"
order: 2
category: "Ophthalmology"
---

# Glaucoma

## Overview

Glaucoma is a group of optic neuropathies characterized by progressive retinal ganglion cell death and optic nerve damage, typically associated with elevated intraocular pressure (IOP). It is the second leading cause of irreversible blindness worldwide, affecting over 70 million people. The disease is often asymptomatic until advanced stages, emphasizing the importance of screening and early detection. Understanding the pathophysiology, risk factors, clinical presentations, and treatment strategies is essential for preventing vision loss.

### Epidemiology
- **Prevalence**: Affects 3-4% of people over age 40
- **Global burden**: 11.2 million bilaterally blind from glaucoma
- **Age-related**: Increases significantly after age 40
- **Ethnic variation**: Higher prevalence in African and Hispanic populations
- **Leading cause**: Second leading cause of blindness globally
- **Asymptomatic**: 50% of patients unaware of their disease

### Classification
- **Primary open-angle glaucoma (POAG)**: Most common (70-90%)
- **Angle-closure glaucoma**: Acute and chronic forms
- **Normal-tension glaucoma**: Subset of POAG with normal IOP
- **Secondary glaucoma**: Due to other ocular or systemic conditions
- **Congenital glaucoma**: Present at birth or early childhood
- **Juvenile glaucoma**: Onset before age 40

## Aqueous Humor Dynamics

### Aqueous Production

#### Site of Production
- **Ciliary body epithelium**: Specifically non-pigmented epithelium
- **Production rate**: 2-3 microliters per minute
- **Total volume**: 250 microliters in anterior and posterior chambers
- **Turnover**: Complete turnover every 90-100 minutes

#### Mechanisms of Production
- **Active secretion**: 80-90% of production
  - Na-K-ATPase pump
  - Carbonic anhydrase involvement
  - Energy-dependent process
- **Ultrafiltration**: 10-20% of production
  - Passive process driven by pressure gradient
  - Through ciliary body capillaries
- **Diffusion**: Minor contribution

#### Factors Affecting Production
- **Circadian rhythm**: Higher during day, lower at night
- **Blood pressure**: Higher systemic BP increases production
- **Autonomic tone**: Beta-adrenergic stimulation increases production
- **Medications**: Beta-blockers, carbonic anhydrase inhibitors reduce production
- **Inflammation**: Reduced production in uveitis

### Aqueous Outflow

#### Conventional (Trabecular) Pathway
- **Route**: Posterior chamber → pupil → anterior chamber → trabecular meshwork → Schlemm canal → collector channels → episcleral veins
- **Percentage**: 80-90% of outflow in young adults
- **Pressure-dependent**: Flow increases with increased IOP
- **Primary site of resistance**: Juxtacanalicular tissue (inner wall of Schlemm canal)

#### Unconventional (Uveoscleral) Pathway
- **Route**: Through ciliary muscle bundles → suprachoroidal space
- **Percentage**: 10-20% in young adults (increases with age and certain medications)
- **Pressure-independent**: Flow relatively constant regardless of IOP
- **Enhanced by**: Prostaglandin analogs

### Intraocular Pressure

#### Normal IOP
- **Mean**: 15-16 mmHg
- **Range**: 10-21 mmHg (statistical normal, not necessarily safe for all individuals)
- **Variation**: ±5 mmHg diurnal fluctuation
- **Peak**: Usually morning
- **Distribution**: Not normally distributed (skewed right)

#### Factors Affecting IOP
- **Age**: Slight increase with age
- **Ethnicity**: Higher in African ancestry
- **Refractive error**: Higher in myopia
- **Central corneal thickness**: Thicker corneas give artificially high readings
- **Time of day**: Diurnal variation
- **Body position**: Higher when supine
- **Exercise**: Transiently lowers IOP
- **Valsalva maneuver**: Transiently increases IOP

## Primary Open-Angle Glaucoma (POAG)

### Pathophysiology

#### Trabecular Meshwork Dysfunction
- **Structural changes**: Thickening of trabecular beams, loss of cells
- **Extracellular matrix**: Accumulation in juxtacanalicular region
- **Endothelial loss**: Progressive loss of trabecular endothelial cells
- **Schlemm canal**: Collapse or narrowing

#### Retinal Ganglion Cell Death
- **Mechanical theory**: IOP causes physical damage at lamina cribrosa
  - Laminar compression and posterior bowing
  - Axonal transport interruption
  - Compression of blood vessels
- **Vascular theory**: Reduced optic nerve head perfusion
  - Optic nerve head blood flow reduction
  - Ischemia and reperfusion injury
  - Dysregulation of autoregulation
- **Excitotoxicity**: Glutamate-mediated cell death
- **Oxidative stress**: Free radical damage
- **Immunologic factors**: Autoimmune mechanisms
- **Genetic factors**: Multiple genes involved

### Risk Factors

#### Major Risk Factors
- **Elevated IOP**: Most important modifiable risk factor
  - Each 1 mmHg increase: 10-12% increased risk
  - However, some develop glaucoma with "normal" IOP
- **Age**: Risk doubles every decade after age 40
- **Family history**: 4-9× increased risk with first-degree relative
- **African ancestry**: 4-5× higher risk, earlier onset, more severe
- **Thin central corneal thickness**: Independent risk factor
  - <555 micrometers associated with increased risk
  - May also underestimate true IOP

#### Other Risk Factors
- **Myopia**: 2-3× increased risk, especially high myopia
- **Diabetes**: Modest increased risk
- **Hypertension**: Controversial, possible increased risk
- **Cardiovascular disease**: Associated with progression
- **Low ocular perfusion pressure**: Difference between BP and IOP
- **Migraine**: May increase risk of progression
- **Sleep apnea**: Associated with glaucoma

### Clinical Presentation

#### Symptoms
- **Early disease**: Usually asymptomatic
- **Advanced disease**:
  - Peripheral vision loss
  - Difficulty with mobility, driving
  - Bumping into objects
  - Central vision preserved until late
- **End-stage**: Tunnel vision, eventual central vision loss

#### Signs

**Optic nerve changes:**
- **Cup-to-disc ratio**: >0.6 or asymmetry >0.2 between eyes
- **Vertical elongation**: Cup becomes vertically oval
- **Notching**: Focal loss of neuroretinal rim (often inferior or superior)
- **Disc hemorrhage**: Splinter hemorrhage at disc margin
- **ISNT rule violation**: Inferior rim should be thickest, then superior, nasal, temporal
- **Peripapillary atrophy**: Beta zone (loss of RPE and choriocapillaris)
- **Laminar dots**: Visible lamina cribrosa pores

**Visual field changes:**
- **Nasal step**: Bjerrum scotoma
- **Arcuate scotoma**: Arc-shaped defect following nerve fiber layer
- **Paracentral scotoma**: Within 10° of fixation
- **Temporal island**: Late finding with preserved temporal field
- **Pattern**: Respects horizontal midline

### Diagnosis

#### Comprehensive Eye Examination
- **Visual acuity**: Usually normal until late disease
- **Pupillary examination**: Relative afferent pupillary defect (RAPD) if asymmetric
- **Gonioscopy**: Essential to classify as open-angle
- **IOP measurement**: Goldmann applanation tonometry (gold standard)
- **Central corneal thickness**: Adjust IOP interpretation
- **Dilated fundus exam**: Optic nerve assessment

#### Optic Nerve Imaging

**Optical coherence tomography (OCT):**
- **Retinal nerve fiber layer (RNFL)**: Thickness measurement
- **Ganglion cell complex**: Macular ganglion cell layer analysis
- **Optic nerve head**: Cup-to-disc ratio, rim area
- **Progression analysis**: Serial scans to detect change

**Stereoscopic optic disc photography:**
- **Documentation**: Baseline and follow-up comparison
- **Rim assessment**: Detailed structural evaluation

#### Visual Field Testing

**Standard automated perimetry (SAP):**
- **24-2 or 30-2 pattern**: Most common
- **SITA (Swedish Interactive Threshold Algorithm)**: Faster, more efficient
- **Indices**:
  - Mean deviation (MD): Overall field depression
  - Pattern standard deviation (PSD): Focal irregularity
  - Visual field index (VFI): Percentage of normal field
- **Glaucoma hemifield test**: Compares superior and inferior hemifields
- **Reliability indices**: False positives, false negatives, fixation losses

**Frequency doubling technology (FDT):**
- **Screening**: Rapid testing
- **Early detection**: May detect before standard fields

#### Additional Testing
- **Diurnal IOP curve**: Multiple IOP measurements throughout day
- **Corneal hysteresis**: Biomechanical properties
- **24-hour IOP monitoring**: Contact lens sensors (research)

### Staging
**Mild glaucoma:**
- Early optic nerve changes
- MD better than -6 dB

**Moderate glaucoma:**
- Progressive optic nerve damage
- MD -6 to -12 dB

**Severe/Advanced glaucoma:**
- Significant optic nerve cupping
- MD worse than -12 dB
- Threat to central vision

### Treatment Principles

#### Target IOP
- **Concept**: IOP at which progression unlikely
- **Initial target**: 20-30% reduction from baseline
- **Reassess**: Based on disease severity and progression
- **Individualized**: Consider age, life expectancy, baseline damage
- **Lower targets**: More aggressive for advanced disease, rapid progression, normal-tension glaucoma

#### Stepwise Approach
1. **Monotherapy**: Start with single agent
2. **Combination therapy**: Add second agent if inadequate response
3. **Laser trabeculoplasty**: If medications insufficient
4. **Incisional surgery**: If laser and medications inadequate

### Medical Treatment

#### Prostaglandin Analogs (First-Line)
**Medications:**
- Latanoprost, travoprost, bimatoprost, tafluprost

**Mechanism:**
- Increase uveoscleral outflow
- Remodel ciliary muscle and extracellular matrix

**Efficacy:**
- 25-35% IOP reduction
- Most effective class

**Dosing:**
- Once daily at bedtime

**Side effects:**
- Conjunctival hyperemia
- Iris pigmentation (permanent)
- Periocular pigmentation (reversible)
- Eyelash growth
- Prostaglandin-associated periorbitopathy (deepening of lid sulcus)
- Cystoid macular edema (risk in aphakic/pseudophakic eyes)

**Contraindications:**
- Uveitis (relative)
- Pregnancy
- Cystoid macular edema

#### Beta-Blockers
**Medications:**
- Timolol, betaxolol, levobunolol, carteolol

**Mechanism:**
- Reduce aqueous production via beta-2 receptor blockade

**Efficacy:**
- 20-25% IOP reduction

**Dosing:**
- Once or twice daily

**Side effects:**
- Bronchospasm, bradycardia, hypotension
- Fatigue, depression
- Sexual dysfunction
- Masking of hypoglycemia symptoms

**Contraindications:**
- Asthma, COPD (absolute for non-selective)
- Heart block, bradycardia
- Decompensated heart failure

#### Alpha-2 Agonists
**Medications:**
- Brimonidine, apraclonidine

**Mechanism:**
- Reduce aqueous production
- Increase uveoscleral outflow

**Efficacy:**
- 20-25% IOP reduction

**Dosing:**
- Two to three times daily

**Side effects:**
- Ocular allergy (common, 10-15%)
- Dry mouth, fatigue
- CNS depression in children (contraindicated <2 years)

#### Carbonic Anhydrase Inhibitors

**Topical (dorzolamide, brinzolamide):**
- Mechanism: Reduce aqueous production
- Efficacy: 15-20% IOP reduction
- Dosing: Two to three times daily
- Side effects: Ocular stinging, bitter taste, allergy

**Systemic (acetazolamide, methazolamide):**
- Mechanism: Same as topical but more potent
- Efficacy: 25-40% IOP reduction
- Dosing: Acetazolamide 250 mg 1-4 times daily
- Side effects: Paresthesias, fatigue, kidney stones, hypokalemia, metabolic acidosis, aplastic anemia (rare)
- Contraindications: Sulfa allergy, sickle cell disease

#### Rho Kinase Inhibitors
**Medications:**
- Netarsudil

**Mechanism:**
- Increase trabecular outflow
- Reduce episcleral venous pressure

**Efficacy:**
- 15-20% IOP reduction

**Side effects:**
- Conjunctival hyperemia (very common)
- Subconjunctival hemorrhage
- Corneal verticillata

#### Combination Medications
- **Fixed combinations**: Improve compliance
  - Cosopt (dorzolamide/timolol)
  - Combigan (brimonidine/timolol)
  - Simbrinza (brinzolamide/brimonidine)
  - Rocklatan (netarsudil/latanoprost)

### Laser Treatment

#### Selective Laser Trabeculoplasty (SLT)
**Mechanism:**
- Low-energy laser to trabecular meshwork
- Selective targeting of pigmented cells
- Biological response: macrophage recruitment, ECM remodeling

**Efficacy:**
- 20-30% IOP reduction in 75-80% of patients
- Effect may wane over 2-5 years
- Repeatable

**Procedure:**
- 50-100 laser spots over 180° or 360° of trabecular meshwork
- Topical anesthesia
- Office-based procedure

**Complications:**
- Transient IOP spike (treat prophylactically)
- Inflammation (treat with topical steroids)
- Rarely: peripheral anterior synechiae

**Indications:**
- First-line alternative to medications
- Medication non-compliance
- Intolerance to medications
- Adjunct to medications

#### Argon Laser Trabeculoplasty (ALT)
- **Older technology**: Higher energy, thermal burns
- **Less commonly used**: Replaced by SLT
- **Not repeatable**: Due to tissue damage

### Surgical Treatment

#### Trabeculectomy
**Mechanism:**
- Create fistula from anterior chamber to subconjunctival space
- Aqueous drains into filtering bleb

**Procedure:**
- Partial-thickness scleral flap
- Remove portion of trabecular meshwork and Schlemm canal
- Suture flap to control flow
- Antimetabolites (mitomycin C or 5-fluorouracil) to reduce scarring

**Success rate:**
- 60-90% achieve target IOP without medications

**Complications:**
- **Early**: Hypotony, shallow anterior chamber, choroidal effusion, suprachoroidal hemorrhage
- **Late**: Bleb leak, infection (endophthalmitis, blebitis), cataract, hypotony maculopathy
- **Vision-threatening**: Endophthalmitis (1-2% lifetime risk)

**Post-operative management:**
- Frequent follow-up
- Topical steroids and antibiotics
- Bleb massage if needed
- Laser suture lysis
- 5-FU injections for scarring

#### Tube Shunt Implants
**Devices:**
- Ahmed glaucoma valve (valved)
- Baerveldt implant (non-valved)
- Molteno implant

**Mechanism:**
- Tube diverts aqueous from anterior chamber to equatorial plate
- Fibrous capsule forms around plate

**Indications:**
- Failed trabeculectomy
- Neovascular glaucoma
- Uveitic glaucoma
- Previous conjunctival scarring

**Complications:**
- Tube erosion, corneal decompensation, diplopia, endophthalmitis
- Hypotony (valved) or hypertensive phase (non-valved)

**Comparison with trabeculectomy:**
- TVT study: Similar efficacy, different complication profiles
- Lower failure rate but higher reoperation rate

#### Minimally Invasive Glaucoma Surgery (MIGS)

**iStent/iStent inject:**
- Trabecular micro-bypass stent
- Ab interno approach
- Combined with cataract surgery
- Mild IOP reduction (15-20%)

**Kahook Dual Blade, Trabectome:**
- Excision of trabecular meshwork
- Ab interno goniotomy
- Mild to moderate IOP reduction

**XEN Gel Stent:**
- Subconjunctival shunt
- Minimally invasive trabeculectomy alternative
- Moderate IOP reduction

**Advantages:**
- Fewer complications than traditional surgery
- Faster recovery
- Often combined with cataract surgery

**Limitations:**
- Less IOP reduction than trabeculectomy
- Best for mild-moderate glaucoma

#### Cyclodestructive Procedures
**Mechanism:**
- Destroy ciliary body to reduce aqueous production

**Types:**
- **Transscleral cyclophotocoagulation**: Diode laser
- **Endoscopic cyclophotocoagulation**: Direct visualization
- **MicroPulse cyclophotocoagulation**: Less tissue damage

**Indications:**
- Refractory glaucoma
- Poor surgical candidates
- Eyes with limited visual potential

**Complications:**
- Inflammation, pain, hypotony, vision loss

## Angle-Closure Glaucoma

### Anatomy and Pathophysiology

#### Anterior Chamber Angle
- **Components**: Cornea, iris, trabecular meshwork, scleral spur, ciliary body
- **Drainage**: Aqueous drains through trabecular meshwork in angle
- **Closure mechanisms**: Iris tissue blocks trabecular meshwork

#### Mechanisms of Angle Closure

**Pupillary block (most common):**
- Resistance to aqueous flow through pupil
- Posterior chamber pressure > anterior chamber pressure
- Iris bows forward (iris bombé)
- Peripheral iris contacts trabecular meshwork

**Plateau iris:**
- Anteriorly rotated ciliary processes
- Peripheral iris bunches in angle
- Can occur despite patent iridotomy

**Lens-related:**
- Phacomorphic: Intumescent lens pushes iris forward
- Lens subluxation: Anterior displacement of lens-iris diaphragm

### Primary Angle-Closure Disease Spectrum

#### Primary Angle-Closure Suspect (PACS)
- **Definition**: Narrow angle on gonioscopy, no other abnormalities
- **IOP**: Normal
- **Optic nerve**: Normal
- **Management**: Observation vs prophylactic laser peripheral iridotomy (LPI)

#### Primary Angle Closure (PAC)
- **Definition**: Angle closure with elevated IOP or peripheral anterior synechiae
- **No optic nerve damage**: No glaucomatous changes
- **Management**: LPI, ± medical therapy

#### Primary Angle-Closure Glaucoma (PACG)
- **Definition**: PAC with glaucomatous optic neuropathy
- **Management**: LPI, medications, ± surgery

### Acute Angle-Closure Crisis

#### Risk Factors
- **Anatomic**: Shallow anterior chamber, thick lens, small eye, plateau iris
- **Age**: Increases with age (lens growth)
- **Sex**: More common in women
- **Ethnicity**: Higher in East Asian, Inuit populations
- **Hyperopia**: Smaller eyes
- **Family history**: Genetic predisposition

#### Precipitating Factors
- **Dim lighting**: Pupil dilation
- **Medications**: Anticholinergics, adrenergic agents, topiramate
- **Emotion**: Stress, excitement
- **Prone positioning**: Forward lens movement

#### Clinical Presentation

**Symptoms:**
- **Severe eye pain**: Unilateral, sudden onset
- **Headache**: Often forehead, brow
- **Nausea and vomiting**: Severe cases
- **Blurred vision**: Marked decrease
- **Halos**: Colored rings around lights (corneal edema)
- **Red eye**: Conjunctival injection

**Signs:**
- **High IOP**: Often 40-80 mmHg
- **Corneal edema**: Hazy cornea
- **Conjunctival injection**: Ciliary flush
- **Mid-dilated pupil**: Non-reactive, vertically oval
- **Shallow anterior chamber**: Peripheral and central
- **Closed angle**: On gonioscopy
- **Iris bombé**: Forward iris bowing

#### Differential Diagnosis
- **Acute uveitis**: Smaller pupil, more cells/flare
- **Corneal abrasion/ulcer**: Fluorescein staining
- **Migraine**: No ocular findings
- **Cluster headache**: Temporal pattern

#### Management

**Immediate treatment:**
1. **Lower IOP medically**:
   - Topical beta-blocker (timolol 0.5%)
   - Topical alpha-agonist (apraclonidine 1% or brimonidine 0.2%)
   - Topical carbonic anhydrase inhibitor (dorzolamide or brinzolamide)
   - Oral carbonic anhydrase inhibitor (acetazolamide 500 mg)
   - Hyperosmotic agent (oral glycerol or IV mannitol) if IOP remains very high

2. **Suppress inflammation**:
   - Topical corticosteroid (prednisolone 1%) every 15 minutes initially

3. **Constrict pupil** (after IOP starts to decrease):
   - Pilocarpine 1-2% (ineffective if IOP very high due to iris ischemia)

**Definitive treatment:**
- **Laser peripheral iridotomy**: Within 24-48 hours after IOP controlled
- **Treat fellow eye**: Prophylactic LPI (high risk of similar attack)

**Surgical options if LPI ineffective:**
- Lens extraction (cataract surgery): Definitive treatment
- Trabeculectomy or tube shunt: If chronic damage present

### Chronic Angle-Closure Glaucoma
- **Insidious**: Gradual synechial angle closure
- **Asymptomatic**: No acute attacks
- **Progressive**: Peripheral anterior synechiae formation
- **Treatment**: LPI, medications, surgery if advanced

## Normal-Tension Glaucoma

### Definition
Glaucomatous optic neuropathy with IOP consistently ≤21 mmHg, in absence of secondary causes.

### Epidemiology
- **Prevalence**: 30-40% of POAG in some populations
- **Ethnicity**: More common in Japanese
- **Gender**: Slight female predominance

### Pathophysiology
- **Vascular theory**: Primary issue is optic nerve head blood flow
- **Impaired autoregulation**: Poor vascular response to pressure changes
- **Systemic vascular disease**: Association with vasospastic disorders
- **Nocturnal hypotension**: Reduced perfusion during sleep
- **CSF pressure**: Low cerebrospinal fluid pressure may increase trans-laminar pressure gradient

### Clinical Features
- **Disc hemorrhages**: More common than in high-pressure glaucoma
- **Deeper cupping**: Relative to amount of field loss
- **Peripapillary atrophy**: Often prominent
- **Visual field defects**: Often deeper, closer to fixation

### Diagnosis
- **Exclude secondary causes**: Rule out prior angle closure, steroid use, etc.
- **Diurnal IOP curve**: Ensure IOP never elevated
- **24-hour monitoring**: Consider if available
- **Systemic evaluation**: Blood pressure, vasospastic history, sleep apnea

### Treatment
- **Target IOP**: 30% reduction from baseline (e.g., 15 mmHg → 10 mmHg)
- **Medical therapy**: Same as POAG
- **Systemic considerations**: Address nocturnal hypotension, sleep apnea
- **Neuroprotection**: Theoretical but unproven benefit

## Secondary Glaucomas

### Exfoliation Glaucoma (Pseudoexfoliation)
- **Mechanism**: Extracellular material deposits in anterior segment
- **Angle**: Open but trabecular meshwork dysfunction
- **Clinical signs**: White flaky material on lens, pupil margin, cornea
- **Characteristics**: Higher IOP, more difficult to control, worse prognosis than POAG
- **Treatment**: More aggressive IOP lowering, often requires surgery

### Pigmentary Glaucoma
- **Mechanism**: Iris pigment liberated and deposited in angle
- **Demographics**: Young myopic males
- **Clinical signs**: Krukenberg spindle, iris transillumination defects, dense trabecular pigmentation
- **IOP fluctuation**: Exercise-induced spikes
- **Treatment**: Medical therapy, LPI (controversial), laser/surgery if needed

### Neovascular Glaucoma
- **Causes**: Retinal ischemia (diabetes, central retinal vein occlusion, ocular ischemic syndrome)
- **Mechanism**: VEGF-driven neovascularization of iris and angle
- **Stages**: Rubeosis iridis → open-angle with elevated IOP → angle-closure from synechiae
- **Treatment**:
  - Address underlying cause (panretinal photocoagulation, anti-VEGF)
  - Medical IOP control
  - Tube shunt surgery if refractory

### Uveitic Glaucoma
- **Mechanisms**: Multiple (trabeculitis, angle closure from synechiae, steroid-induced)
- **Treatment**: Control inflammation, IOP management, avoid prostaglandins if active inflammation

### Steroid-Induced Glaucoma
- **Mechanism**: Increased trabecular meshwork resistance
- **Risk factors**: Genetic susceptibility, longer duration, higher potency steroids
- **Management**: Discontinue or reduce steroids if possible, IOP-lowering medications

### Traumatic Glaucoma
- **Acute**: Hyphema causing trabecular obstruction, angle recession
- **Chronic**: Angle recession glaucoma, damage to trabecular meshwork
- **Management**: Treat hyphema, long-term monitoring for late glaucoma development

## Childhood Glaucomas

### Primary Congenital Glaucoma
- **Age**: Birth to 3 years
- **Inheritance**: Often sporadic, some autosomal recessive
- **Mechanism**: Trabecular meshwork maldevelopment
- **Signs**: Epiphora, photophobia, blepharospasm, buphthalmos (enlarged globe), corneal edema, Haab striae (breaks in Descemet membrane)
- **Treatment**: Surgery (goniotomy, trabeculotomy, trabeculectomy with antimetabolites)

### Juvenile Open-Angle Glaucoma
- **Age**: 3-40 years
- **Genetics**: Often MYOC gene mutations
- **Presentation**: Similar to adult POAG
- **Treatment**: Medical therapy, often requires surgery

## Monitoring and Follow-Up

### Stable Glaucoma
- **IOP**: Every 3-6 months
- **Visual fields**: Every 6-12 months
- **Optic nerve exam/imaging**: Every 6-12 months

### Progressive or Advanced Glaucoma
- **More frequent monitoring**: Every 1-3 months
- **Treatment adjustment**: Lower target IOP
- **Consider surgery**: If medical therapy insufficient

### Progression Analysis
- **Structural**: OCT RNFL thinning
- **Functional**: Visual field MD/VFI decline
- **Trend analysis**: Requires multiple data points over time
- **Clinical judgment**: Integrate all data

## Patient Education and Compliance

### Adherence Challenges
- **Asymptomatic disease**: No immediate feedback from treatment
- **Complex regimen**: Multiple medications, multiple times daily
- **Side effects**: Local and systemic

### Strategies to Improve Compliance
- **Education**: Explain disease, importance of treatment
- **Simplify regimen**: Once-daily medications, fixed combinations
- **Address side effects**: Switch medications if intolerable
- **Regular follow-up**: Reinforce importance
- **Family involvement**: Support system

## Prognosis

### Factors Affecting Prognosis
- **Baseline damage**: More advanced disease, worse prognosis
- **IOP control**: Better control, better outcomes
- **Progression rate**: Faster progression needs more aggressive treatment
- **Age**: Younger patients have more years at risk
- **Life expectancy**: Consider functional vision over patient's lifetime

### Functional Outcomes
- **Most patients**: Maintain functional vision throughout life with treatment
- **Bilateral blindness**: Rare with modern management
- **Quality of life**: Vision-related quality of life can be preserved

## Future Directions

### Neuroprotection
- **Goal**: Protect retinal ganglion cells independent of IOP
- **Targets**: Glutamate excitotoxicity, oxidative stress, neurotrophic factors, immune modulation
- **Status**: No proven neuroprotective agents yet

### Novel IOP-Lowering Strategies
- **New drug targets**: Adenosine receptors, nitric oxide, other pathways
- **Sustained-release**: Drug delivery implants
- **Gene therapy**: Experimental

### Improved Diagnostics
- **Earlier detection**: Before irreversible damage
- **Better progression detection**: Artificial intelligence, structure-function relationships
- **Personalized risk assessment**: Genetic testing, biomarkers

### Surgical Advances
- **MIGS refinement**: Improved devices, techniques
- **Sustained drug delivery**: Combined with surgery
- **Regenerative medicine**: Stem cells, tissue engineering

## Summary

Glaucoma is a leading cause of irreversible blindness characterized by progressive optic nerve damage, usually associated with elevated IOP. Early detection through screening is critical as the disease is often asymptomatic until advanced. Primary open-angle glaucoma is most common, but angle-closure and various secondary glaucomas must be recognized. Treatment focuses on lowering IOP through medications, laser, or surgery. Regular monitoring for progression and patient education about adherence are essential for preserving vision throughout the patient's lifetime. While challenging, glaucoma can be successfully managed in most patients with modern therapy, preventing blindness and maintaining quality of life.
